Nature Medicine · 1 July 2026 · From issue 04

A double-acting HIV antibody was safe and well tolerated in its first human trial.

Deborah A. Theodore, Bryan T. Mayer et al., Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial, Nature Medicine.

Integrity screen: passed (3 checks) Checked 11 August 2026. Read the source

The plain-language reading of this paper is in the full issue, for subscribers.

Read the full issue

Get it free, every two days

Five papers free every issue, about 15 emails a month. No spam. Leave in one click.

Also in issue 04 10 papers

A new statistical test can show if custom treatments beat one-size-fits-all options.
Science
Roots can detect and steer away from rotting plant matter using acid signals in soil.
Science
A new cell transplant for Parkinson's disease looked safe in a small early trial.
Nature Medicine
A giant 8 million dalton machine in methane making microbes forms one continuous electron loop.
Nature
Two hunger related brain signals control whether ants care for baby ants or go find food instead.
Nature
A computer-designed metal recipe resists cracking better than any past version, while staying strong in extreme heat.
Nature Communications
Random, unsynced nucleus division plus crowding-based branching keeps nuclei evenly spaced in this fungus.
Proceedings of the National Academy of Sciences
One nerve connection in a worm uses three different channel proteins working together.
Proceedings of the National Academy of Sciences
Most US lakes switched from trapping phosphorus to trapping nitrogen over ten years.
Nature Communications